NVO | Novo Nordisk A/S Stock Overview

(Stock Exchange: NYSE)

Day's Range	79.32 - 81.11
52 Week Range	78.17 - 148.15
Beta	0.50
Implied Volatility	45.61%
IV Rank	61.06%
Day's Volume	7,858,098
Average Volume	7,395,511
Shares Outstanding	4,324,541,638
Market Cap	350,417,608,927
Sector	Healthcare
Industry	Biotechnology
IPO Date	1981-04-30

Valuation
Profitability
Growth
Health
P/E Ratio	27.66
Forward P/E Ratio	48.17
EPS	2.93
1YR Price Target	77.75
Dividend Yield	1.31%
Dividend Per Share	1.13
Dividend ExDate	2023-08-18
Dividend PayDate	2023-08-29
Employees	71,880
Country	Denmark
Website	NVO

Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

NVO's peers: CRSP, REGN, SRPT, NTLA, MRNA, CVAC, NVAX, CWBR, RETA, BNTX, DNA, VRTX, BMRN, SGEN, ALNY, MDGL, ICPT, TGTX, TERN, HEPA

*Chart delayed

Analyzing fundamentals for NVO we got that it has strong fundamentals where Valuation is considered to be slightly undervalued, Profitability is stunning wealthy, Growth is exceptionally good and Health is passable. For more detailed analysis please see NVO Fundamentals page.

Watching at NVO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NVO Technicals page.